People’s Financial News, February 12 — GeBioBiotics announced today that it has received a $30 million strategic equity investment from Sanofi. This round of funding will support the research and development of GeBioBiotics’ two core projects, GLB-005 and GLB-007, both of which are expected to become disease-modifying therapies for sickle cell disease.
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Geboson Biotech receives $30 million strategic equity investment from Sanofi
People’s Financial News, February 12 — GeBioBiotics announced today that it has received a $30 million strategic equity investment from Sanofi. This round of funding will support the research and development of GeBioBiotics’ two core projects, GLB-005 and GLB-007, both of which are expected to become disease-modifying therapies for sickle cell disease.